CD19 and diffuse large B-cell lymphoma: Recently, two novel anti-CD19 monoclonal antibodies have been approved by the FDA, including tafasitamab and loncastuximab tesirine, which have been propagated as viable options for the treatment of R/R diffuse large B-cell lymphoma (DLBCL).